Mapping Lipid Rewiring During Drug-Induced Cell Death
Fiber-based imaging platform reveals nanoscale heterogeneity and drug-specific metabolic fingerprints in cancer cells
Clinical Scorecard: Mapping Lipid Rewiring During Drug-Induced Cell Death
At a Glance
| Category | Detail |
|---|
| Condition | Drug-Induced Apoptosis |
| Key Mechanisms | Lipid metabolism and remodeling during cell death |
| Target Population | Cancer cells (e.g., HeLa and HepG2) |
| Care Setting | Research laboratories |
Key Highlights
- Development of a mass spectrometry imaging platform for single-cell lipid visualization
- Achieves ~800 nm spatial resolution, surpassing traditional methods
- Observes dose- and time-dependent lipid remodeling in response to anticancer agents
- Distinct lipid fingerprints produced by different drugs
- Broader applicability demonstrated in imaging mouse brain tissue
Guideline-Based Recommendations
Diagnosis
- Utilize high-resolution mass spectrometry imaging to assess lipid changes during apoptosis
Management
- Incorporate lipid profiling in drug development and precision medicine strategies
Monitoring & Follow-up
- Monitor lipid metabolism shifts to evaluate drug efficacy and cellular responses
Risks
- Consider variability in lipid responses among individual cells within the same population
Patient & Prescribing Data
Patients undergoing treatment with anticancer agents
Linking metabolic changes to cellular phenotypes may enhance treatment personalization
Clinical Best Practices
- Employ mass spectrometry imaging for detailed lipid analysis in cancer research
- Integrate lipid profiling into clinical trials for better understanding of drug mechanisms
References
